RIGI and neoplasm: Moreover, targeting RLR signaling with the RIG-I agonist stem loop RNA 14 (SLR14) inhibited tumor growth in murine cancer models [54, 55], which was associated with enhanced anti-tumor CD8+ T cell responses.